Hawthrone Effect, a San Francisco CA-based company which offers solutions for decentralizing clinical trials, raised $20M in Series A funding.
The round was led by Northpond Ventures, with participation from SignalFire and P5 Health Ventures.
The company intends to use the funds to accelerate growth and help scale operations.
Led by Jodi Akin, CEO and founder, Hawthorne Effect provides a solution for decentralizing clinical trials to alleviate key issues related to patient recruitment and retention via its tech-driven platform and expansive network of medical professionals. The company’s tech-driven platform, the Hawthorne Cloud, works with highly trained medical professionals, called Hawthorne Heroes, to deliver complete assessments whenever, wherever and however the trial and patient require.
Since launching in 2015, the solution has been used across more than 50 clinical trials. The company is actively engaged with more than 260 clinical sites and also runs trials as a single virtual site.